Know Cancer

or
forgot password

A Phase II, Open-Label Study of Pazopanib (GW786034) in Patients With Relapsed or Refractory Multiple Myeloma


Phase 2
21 Years
N/A
Not Enrolling
Both
Multiple Myeloma, Carcinoma, Renal Cell

Thank you

Trial Information

A Phase II, Open-Label Study of Pazopanib (GW786034) in Patients With Relapsed or Refractory Multiple Myeloma

Inclusion Criteria


Inclusion criteria:

- Must have diagnosis of relapsed or refractory multiple.

- bone marrow function [ANC (absolute neutrophil count) greater than 1000/mm3];
platelet count greater than or equal to 75,000/mm3.

- renal function (calculated creatinine clearance >50 mL.min, albumin less than or
equal to 500 mg).

Exclusion criteria:

- Failed more than 3 prior lines of therapy including stem cell transplant.

- Females who are pregnant or nursing.

- Unstable blood pressure.

- Significant heart conditions or history of thrombosis.

- Any unstable, pre-existing major medical condition or history of other cancers.

- Have received an investigational drug, chemotherapy, radiation treatment or surgery
within 28 days prior to entering the study.

Type of Study:

Interventional

Study Design:

Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Outcome Measure:

Evaluate the safety and tolerability of GW786034 in patients with relapsed or refractory multiple myeloma (MM).

Principal Investigator

GSK Clinical Trials

Investigator Role:

Study Director

Investigator Affiliation:

GlaxoSmithKline

Authority:

Australia: National Health and Medical Research Council

Study ID:

VEG20006

NCT ID:

NCT00256880

Start Date:

January 2005

Completion Date:

December 2005

Related Keywords:

  • Multiple Myeloma
  • Carcinoma, Renal Cell
  • Pazopanib(GW786034)
  • Solid Tumors
  • Myeloma
  • Carcinoma
  • Carcinoma, Renal Cell
  • Multiple Myeloma
  • Neoplasms, Plasma Cell

Name

Location

GSK Investigational SiteLittle Rock, Arkansas  72205
GSK Investigational SiteSpringfield, Massachusetts  01107
GSK Investigational SiteRaleigh, North Carolina  27609
GSK Investigational SitePittsburgh, Pennsylvania  15213
GSK Investigational SiteSeattle, Washington  98133